Exploration has established that medication with the aptitude to inhibit the CYP enzyme process may possibly have an impact about the metabolic clearance of 3-MMC, making the drug considerably more extended-lasting and soaring the potential risk of adverse consequences. ** ** ** ** ** ** ** ** ******** ** ** *** *** ** ** ** ** ** ** ** ** ****